WO1992005151A1 - Crystallization of optical isomers of leukotriene antagonists - Google Patents

Crystallization of optical isomers of leukotriene antagonists Download PDF

Info

Publication number
WO1992005151A1
WO1992005151A1 PCT/US1991/006862 US9106862W WO9205151A1 WO 1992005151 A1 WO1992005151 A1 WO 1992005151A1 US 9106862 W US9106862 W US 9106862W WO 9205151 A1 WO9205151 A1 WO 9205151A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
alkyl
alkoxy
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006862
Other languages
French (fr)
Inventor
Trevor Laird
Robert John Mills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to SK21993A priority Critical patent/SK21993A3/en
Priority to AU87675/91A priority patent/AU662299B2/en
Priority to CS93451A priority patent/CZ45193A3/en
Publication of WO1992005151A1 publication Critical patent/WO1992005151A1/en
Priority to KR1019930700813A priority patent/KR930702284A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to certain amine salts of leukotriene antagonists and the use of certain amines to form these salts as a means for crystallizing selectively optical isomers of the leukotriene antagonists recited herein.
  • SRS-A Slow Reacting Substance of Anaphylaxis
  • SRS-A has been shown to be a highly potent bronchoconstricting substance which is released primarily from mast cells and basophils on antigenic challenge.
  • SRS-A has been proposed as a primary mediator in human asthma.
  • SRS-A in addition to its pronounced effects on lung tissue, also produces permeability changes in skin and may be involved in acute cutaneous allergic reactions. Further, SRS-A has been shown to effect depression of ventricular contraction and p ⁇ tentiation of the cardiovascular effects of histamine. Antagonists to SRS substances have been developed in an attempt to provide relief from the disease conditions giving rise to or resulting from these compounds.
  • A is 1 and X is 1 or 2;
  • Rl is C8 to C1 3 alkyl, C ⁇ to C 1 2 alkoxy, C7 to C12 alkylthio, Cio to C 12 1-alkynyl, 10-undecynyloxy, 11-dodecynyl, phenyl-C4 to Ci o alkyl, phenyl-C3 to C9 alkoxy, phenylthio-C ⁇ to C9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, Ci to C4 alkoxy, methylthio or trifluoromethylthio, furyl-C4 to Cio alkyl, trifluoromethyl-C7 to C 12 alkyl or cyclohexyl-C4 to Cio alkyl; q is 0, 1 or 2, with the proviso that Ri is not alkylthio or phenylthioalkyl when q is 1 or 2;
  • Y is COR3, C(R4)H(CH 2 ) m COR3, or (CH2) ⁇ -l-C-tetrazolyl;
  • R3 is 0"» amino, or Ci to C ⁇ alkoxy,
  • R4 is hydrogen, methyl, C to C4-alkoxy, fluoro or hydroxy; m is 0, 1, or 2; R is (CH 2 ) n COR6; n is 0 to 6;
  • R is O", amino, or Ci to C6-alkoxy; with the proviso that at least one of Y or R must have an R 3 or R6 group respectively which is O".
  • This invention also relates to a process for separating a single isomer, either the R or S form, from a racemic mixture of a compound of formula II
  • R, Ri, q and Y are defined above with the proviso that R3 and R ⁇ are R3' and R & where R 3 1 and R ⁇ ' are independently -OH, amino, or C i to CO alkoxy, with the further proviso that at least one of R 3 > or R ⁇ $ must be -OH or a salt thereof, which process comprises treating a racemic mixture of formula II with about 0.5 to 2.5 equivalents, relative to the number of carboxylic acid groups in the formula, of either (R)-4-nitro- ⁇ -methylbenzenemethanamine or (S)-4-nitro- ⁇ - methylbenzenemethanamine, recovering a crystalline salt, and converting the salt to an acid or a pharmaceutically acceptable salt. It is preferred to use 0.5 to 1.5 equivalents of the nitro compound per carboxylic acid group in formula II. This process yields a substantially pure single enantiomer from a racemic mixture.
  • a preferred class of salts are those of formula (IA)
  • A is 1, X is 1 or 2, and Ri and R are described above.
  • Ri is defined above, particularly where Ri is phenylalkyl.
  • Most preferred among the salts of this group are: the bis-(R)-4-nitro- ⁇ -methylbenzenemethanamine salt of (S)- ⁇
  • Ri is described above, particularly where Ri is phenylalkyl.
  • the salts of the formula (IC) are exemplified by the following compounds: the bis-(R)-4-nitro- ⁇ -methylbenzenemethanamine salt of (R)- ⁇ - [(2-carboxyethyl)thio]-2-(l-dodecyl)benzeneacetic acid; and the bis-(R)-4-nitro- ⁇ -methylbenzenemethanamine salt of (R)- ⁇ -[(2- carboxyethyl)thio]-2-(8-phenyloctyl)benzeneacetic acid.
  • Ri is defined above, particularly where Ri is phenylalkyl.
  • the compounds of formula (ID) are exemplified by the following compounds : the bis-(R)-4-nitro- ⁇ -methylbenzenemethanamine salt of [R- (R*,S*)]- ⁇ -[(2-carboxyethyl)thio]- ⁇ -hydroxy-2-(8-phenyloctyl)- benzenepropanoic acid; and the bis-(R)-4-nitro- ⁇ -methylbenzenemethanamine salt of [R-(R*,S*)]- ⁇ -[(2-carboxyethyl)thio]- ⁇ -hydroxy-2-(l -dodecyl)- benzenepropanoic acid.
  • racemates of formula II In a process for resolving racemates of formula II, the following sets of general and specific compounds are preferred. A set of preferred racemates are those of formula (IIB),
  • Ri is a phenyl-C_
  • Most particularly racemates of formula (IIB) can be treated with the (R)-4- nitro- ⁇ -methylbenzenemethanamine to obtain, after further manipulation, the isomers (S)- ⁇ -[(2-carboxyethyl)thio]-2-(l - dodecyl)berizenepropanoic acid and (S)- ⁇ -[(2-carboxyethyl)thio]-2-(8- phenyloctyl)benzenepropanoic acid.
  • racemates of formula (IID) can be treated with (R)-4- nitro- ⁇ -methylbenzenemethanamine to obtain, after further manipulation, the isomer [R-(R*,S*)]- ⁇ -[(2-carboxyethyl)thio]- ⁇ - hydroxy-2-(8-phenyloctyl)benzenepropanoic acid.
  • the racemates of this invention can be prepared according to the disclosure set out in United States Patent number 4,820,719 issued April 11, 1989. That disclosure, in full, is incorporated herein by reference as if set out herein.
  • the amine, (R)-4-nitro- ⁇ -methylbenzenemethanamine can be purchased as a hydrochloride salt from a commercial source such as Chiron, a Norwegian company. Or the hydrochloride salt may be made by the process of Baker, J. W. & Ingold, C.K., J. Chem. Soc. 261-264, 1927, and the R and S isomers fractionally crystallized by the method of Nerdel, F. and Liebeg, H., Ann 621 :42-50, 1959. A more recent process for making the hydrochloride salt of this amine is given in Perry, C.W. et al, Synthesis 492-494, 1977.
  • the amine can be prepared by treating the hydrochloride salt with a strong base and extracting the amine into an organic solvent, for example methylene chloride or toluene. Amine prepared in this manner may be stored prior to use. Alternatively, the amine can be liberated in-situ by treating the hydrochloride salt with a strong base in an aqueous alcoholic solvent, and then used immediately.
  • an organic solvent for example methylene chloride or toluene.
  • Amine prepared in this manner may be stored prior to use.
  • the amine can be liberated in-situ by treating the hydrochloride salt with a strong base in an aqueous alcoholic solvent, and then used immediately.
  • This amine is a particularly effective resolving agent for separating out a particular isomer from a racemic mixture of compounds denoted by formula II.
  • a salt is formed between the amine and the carboxylate function. This salt can be fractionally crystallized, giving a salt comprising the amine and just one isomer of the acid. An alcohol is the preferred solvent for crystallization. This method provides excellent selectivity for the desired isomer.
  • salts may be converted to the corresponding acid by means of a dilute acid. Or they may be converted to another salt, such as an alkali metal salt, by treating a solution of the isolated salt with a base.
  • the salt can be converted to the free acid by treating a solution of that salt with dilute mineral acid, for example 0.5N HC1 at room temperature or thereabouts. The mixture is then extracted with an appropriate organic solvent, or subjected to other convenient separatory means, and the pure isomer obtained as the free acid after removing the solvent.
  • Racemic ⁇ -[(2-carboxyethyl)thio] -2-(8-phenyloctyl)- benzenepropanoic acid [6.05 g (60.7% assay, 8.3 mmol)] was dissolved in 80 mL of 2-propanol and treated with a solution of 1.48 g (8.9 mmol) of (R)-4-nitro- ⁇ -methylbenzenemethanamine in 2-propanol. The mixture was heated to reflux, then allowed to cool to 0°C. The resulting solids were isolated by filtration to afford, after drying, 2.33 g of crude product. Chiral HPLC analysis indicated 97.7% of the desired S-enantiomer.
  • Example 3 Determination and Confirmation of Absolute Configuration Both (S)- ⁇ -[(2-carboxyethyl)thio]-2-(8-phenyloctyl)- benzenepropanoic acid and [R-(R*,S*)]- ⁇ -[(2-carboxyethyl)thio]- ⁇ - hydroxy-2-(8-phenyloctyl)benzenepropanoic acid react with two molar equivalents of (R)-4-iodo- ⁇ -methylbenzenemethanamine to produce highly crystalline salts. In each of these salts, the absolute configuration of the diacid portion was determined unambiguously by single crystal x-ray analysis.
  • each salt was treated with aqueous acid and extracted with ethyl acetate.
  • HPLC column cellulose tris-3,5-dimethylphenylcarbamate chiral stationary phase, coated on silica gel

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to salts of formula (I) where, A is 1 and X is 1 or 2; R1 is C8 to C13 alkyl, C7 to C12 alkoxy, C7 to C12 alkylthio, C10 to C12 1-alkynyl, 10-undecynyloxy, 11-dodecynyl, phenyl-C4 to C10 alkyl, phenyl-C3 to C9 alkoxy, phenylthio-C3 to C9 alkyl with the phenyl unsubstituted or monosubstituted with bromo, chloro, trifluoromethyl, C1 to C4 alkoxy, methylthio or trifluoromethylthio, furyl-C4 to C10 alkyl, trifluoromethyl-C7 to C12 alkyl or cyclohexyl-C4 to C10 alkyl; q is 0, 1 or 2, with the proviso that R1 is not alkylthio or phenylthioalkyl when q is 1 or 2; Y is COR3, C(R4)H(CH2)mCOR3, or (CH2)0-1-C-tetrazolyl; R3 is 0-, amino, or C¿1? to C6 alkoxy, R4 is hydrogen, methyl, C1 to C4-alkoxy, fluoro or hydroxy; m is 0, 1, or 2; R is (CH2)nCOR6; n is 0 to 6; R6 is 0?-¿, amino, or C¿1? to C6-alkoxy; with the proviso that at least one of Y or R must have an R3 or R6 group respectively which is 0?-¿ and the use of certain amines to form these salts as a means for selectively crystallizing optical isomers of the leukotriene antagonists recited herein.

Description

CRYSTALLIZAΉON OF OPTICAL ISOMERS OF LEUKOTRIENE
ANTAGONISTS
SCOPE OF THE INVENTION This invention relates to certain amine salts of leukotriene antagonists and the use of certain amines to form these salts as a means for crystallizing selectively optical isomers of the leukotriene antagonists recited herein.
BACKGROUND OF THE INVENTION
"Slow Reacting Substance of Anaphylaxis" (SRS-A) has been shown to be a highly potent bronchoconstricting substance which is released primarily from mast cells and basophils on antigenic challenge. SRS-A has been proposed as a primary mediator in human asthma. SRS-A, in addition to its pronounced effects on lung tissue, also produces permeability changes in skin and may be involved in acute cutaneous allergic reactions. Further, SRS-A has been shown to effect depression of ventricular contraction and pόtentiation of the cardiovascular effects of histamine. Antagonists to SRS substances have been developed in an attempt to provide relief from the disease conditions giving rise to or resulting from these compounds. A number of the compounds developed are normally prepared as a racemic mixture, though activity lies primarily or completely in just one of the optical isomers. Resolving these mixtures is a useful, if not necessary step in preparing a useful formulation for treating these diseases. It has now been found that for certain compounds, the ones set out below, this can bε accomplished most readily and inexpensively by means of (R)-4- nitro-α-methylbenzenemethanamine. This amine is uniquely suited to resolving certain enantiomers of the compounds given below so that the most active isomer can be obtained for use in treating SRS-related diseases.
DETAILED DESCRIPTION OF THE INVENTION The compounds of this invention are (R)-4-nitro-cc-methyl- benzenemethanamine salts of formula I Formula I
Figure imgf000004_0001
where:
A is 1 and X is 1 or 2;
Rl is C8 to C13 alkyl, Cη to C12 alkoxy, C7 to C12 alkylthio, Cio to C 12 1-alkynyl, 10-undecynyloxy, 11-dodecynyl, phenyl-C4 to Ci o alkyl, phenyl-C3 to C9 alkoxy, phenylthio-Cβ to C9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, Ci to C4 alkoxy, methylthio or trifluoromethylthio, furyl-C4 to Cio alkyl, trifluoromethyl-C7 to C12 alkyl or cyclohexyl-C4 to Cio alkyl; q is 0, 1 or 2, with the proviso that Ri is not alkylthio or phenylthioalkyl when q is 1 or 2;
Y is COR3, C(R4)H(CH2)mCOR3, or (CH2)θ-l-C-tetrazolyl;
R3 is 0"» amino, or Ci to Cβ alkoxy,
R4 is hydrogen, methyl, C to C4-alkoxy, fluoro or hydroxy; m is 0, 1, or 2; R is (CH2)nCOR6; n is 0 to 6;
R is O", amino, or Ci to C6-alkoxy; with the proviso that at least one of Y or R must have an R3 or R6 group respectively which is O". This invention also relates to a process for separating a single isomer, either the R or S form, from a racemic mixture of a compound of formula II
Figure imgf000004_0002
where R, Ri, q and Y are defined above with the proviso that R3 and Rβ are R3' and R& where R3 1 and Rό' are independently -OH, amino, or C i to CO alkoxy, with the further proviso that at least one of R3> or R<$ must be -OH or a salt thereof, which process comprises treating a racemic mixture of formula II with about 0.5 to 2.5 equivalents, relative to the number of carboxylic acid groups in the formula, of either (R)-4-nitro-α-methylbenzenemethanamine or (S)-4-nitro-α- methylbenzenemethanamine, recovering a crystalline salt, and converting the salt to an acid or a pharmaceutically acceptable salt. It is preferred to use 0.5 to 1.5 equivalents of the nitro compound per carboxylic acid group in formula II. This process yields a substantially pure single enantiomer from a racemic mixture. A preferred class of salts are those of formula (IA)
Figure imgf000005_0001
wherein A is 1, X is 1 or 2, and Ri and R are described above.
Another preferred group of these salts are 3-aryl-propionates of formula (IB)
Figure imgf000005_0002
wherein Ri is defined above, particularly where Ri is phenylalkyl. Most preferred among the salts of this group are: the bis-(R)-4-nitro-α-methylbenzenemethanamine salt of (S)-β
[(2-carboxyethyl)thio]-2-(l-dodecyl)benzenepropanoic acid; and the bis-(R)-4-nitro-α-methylbenzenemethanamine salt of (S)-β-[(2- carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid. Another preferred group of salts are the aryl-acetates of formula (IC).
Figure imgf000006_0001
where Ri is described above, particularly where Ri is phenylalkyl.
The salts of the formula (IC) are exemplified by the following compounds: the bis-(R)-4-nitro-α-methylbenzenemethanamine salt of (R)-α- [(2-carboxyethyl)thio]-2-(l-dodecyl)benzeneacetic acid; and the bis-(R)-4-nitro-α-methylbenzenemethanamine salt of (R)-α-[(2- carboxyethyl)thio]-2-(8-phenyloctyl)benzeneacetic acid.
Another preferred group of salts are 3-aryl- 2-hydroxypropionates of formula (ID)
Figure imgf000006_0002
where Ri is defined above, particularly where Ri is phenylalkyl.
The compounds of formula (ID) are exemplified by the following compounds : the bis-(R)-4-nitro-α-methylbenzenemethanamine salt of [R- (R*,S*)]-β-[(2-carboxyethyl)thio]-α-hydroxy-2-(8-phenyloctyl)- benzenepropanoic acid; and the bis-(R)-4-nitro-α-methylbenzenemethanamine salt of [R-(R*,S*)]-β-[(2-carboxyethyl)thio]-α-hydroxy-2-(l -dodecyl)- benzenepropanoic acid.
In a process for resolving racemates of formula II, the following sets of general and specific compounds are preferred. A set of preferred racemates are those of formula (IIB),
Figure imgf000007_0001
more particularly those where Ri is a phenyl-C_|. to Cio-alkyl. Most particularly racemates of formula (IIB) can be treated with the (R)-4- nitro-α-methylbenzenemethanamine to obtain, after further manipulation, the isomers (S)-β-[(2-carboxyethyl)thio]-2-(l - dodecyl)berizenepropanoic acid and (S)-β-[(2-carboxyethyl)thio]-2-(8- phenyloctyl)benzenepropanoic acid.
Another set of preferred racemates are those of formula IIC
Figure imgf000007_0002
particularly those where Ri is a phenyl-C4 to Cio alkyl. Most particularl racemates of formula (IIC) can be treated with (R)-4-nitro-α- methylbenzenemethanamine to obtain, after further manipulation, the isomers (R)-α-[(2-carboxyethyl)thio]-2-(l -dodecyl)benzeneacetic acid and (R)-α-[(2-carboxyethyl)thio]-2-(8-phenyloctyl)benzeneacetic acid. Yet another preferred set of racemates are the 2S*,3R*-isomers represented by formula (IID),
Figure imgf000007_0003
particularly those where R is a phenyl-C4 to Cio-alkyl. Most particularly the racemate of formula (IID) can be treated with (R)-4- nitro-α -methylbenzenemethanamine to obtain, after further manipulation, the isomer [R-(R*,S*)]-β-[(2-carboxyethyl)thio]-α- hydroxy-2-(8-phenyloctyl)benzenepropanoic acid. The racemates of this invention can be prepared according to the disclosure set out in United States Patent number 4,820,719 issued April 11, 1989. That disclosure, in full, is incorporated herein by reference as if set out herein.
The amine, (R)-4-nitro-α-methylbenzenemethanamine, can be purchased as a hydrochloride salt from a commercial source such as Chiron, a Norwegian company. Or the hydrochloride salt may be made by the process of Baker, J. W. & Ingold, C.K., J. Chem. Soc. 261-264, 1927, and the R and S isomers fractionally crystallized by the method of Nerdel, F. and Liebeg, H., Ann 621 :42-50, 1959. A more recent process for making the hydrochloride salt of this amine is given in Perry, C.W. et al, Synthesis 492-494, 1977. The amine can be prepared by treating the hydrochloride salt with a strong base and extracting the amine into an organic solvent, for example methylene chloride or toluene. Amine prepared in this manner may be stored prior to use. Alternatively, the amine can be liberated in-situ by treating the hydrochloride salt with a strong base in an aqueous alcoholic solvent, and then used immediately.
This amine is a particularly effective resolving agent for separating out a particular isomer from a racemic mixture of compounds denoted by formula II. A salt is formed between the amine and the carboxylate function. This salt can be fractionally crystallized, giving a salt comprising the amine and just one isomer of the acid. An alcohol is the preferred solvent for crystallization. This method provides excellent selectivity for the desired isomer.
These salts may be converted to the corresponding acid by means of a dilute acid. Or they may be converted to another salt, such as an alkali metal salt, by treating a solution of the isolated salt with a base. For example, the salt can be converted to the free acid by treating a solution of that salt with dilute mineral acid, for example 0.5N HC1 at room temperature or thereabouts. The mixture is then extracted with an appropriate organic solvent, or subjected to other convenient separatory means, and the pure isomer obtained as the free acid after removing the solvent.
The following examples illustrate the process for making and preparing the compounds of this invention. Being examples they are not to be considered as limiting the invention set forth in the claims appended hereto. Example 1 Preparation of (S)-β-lΥ2-Carboxyethvnthiol -2-r8- phenyloctyPbenzenepropanoic acid, compound with (R)-4-Nitro-α- methylbenzenemethanamine (1 :2)
Racemic β-[(2-carboxyethyl)thio] -2-(8-phenyloctyl)- benzenepropanoic acid [6.05 g (60.7% assay, 8.3 mmol)] was dissolved in 80 mL of 2-propanol and treated with a solution of 1.48 g (8.9 mmol) of (R)-4-nitro-α-methylbenzenemethanamine in 2-propanol. The mixture was heated to reflux, then allowed to cool to 0°C. The resulting solids were isolated by filtration to afford, after drying, 2.33 g of crude product. Chiral HPLC analysis indicated 97.7% of the desired S-enantiomer. After recrystallizing from 2-propanol, the content of S-enantiomer was enhanced to >99.5%. The salt contained 2 moles of amine per mole of diacid: Mp 239-240°C; [CC]D25 = -8.9° (c=1.0, methanol); Chiral HPLC (Bakerbond Chiralcel OD, 4.6 mm x 250 mm, 3.5/96.5/0.1 isopropanόl/n-hexane/trifluoroacetic acid, 2.0 mL/min, ambient temperature, UV detection at 215 nm): Retention Time = 15.9 min (minor peak; R-enantiomer), Retention Time = 19.4 min (major peak; S-enantiomer); Anal. Calcd for C42H54N4O8S: C, 65.09; H, 7.02; N, 7.23; S, 4.14. Found: C ,65.11; H, 7.00; N, 7.39; S, 4.09; H NMR (CDCI3/CD3OD, 270 MHz) δ 8.21-8.24 (m, 4H), 7.57-7.60 (m, 4H), 7.14-
7.39 (m, 9H), 4.47-4.53 (t, 1H), 4.30-4.38 (q, 2H, J=6.6 Hz), 2.32-2.91 (m, 10H), 1.32-1.60 (br, 18H). Example 2
Preparation of rR-('R*.S* 1-β-r(2-Carboxyethvnthio1-α-hvdroxy-2-(8 - phenyloctyPbenzenepropanoic acid, compound with (RV4-Nitro-α- methylbenzenemethan amine.d :2) A solution of racemic (R*,S*)-β-[(2-carboxyethyl)thio]-α- hydroxy-2-(8-phenyloctyl)benzenepropanoic acid (2.32g, 6.6 mmol) was prepared by warming the acid in 40 mL of 2-propanol. The resulting solution was treated with 2.32 g (13.9 mmol) of (R)-4-nitro- α -methylbenzenemethanamine in 50 mL of absolute ethanol. The solution was heated to reflux, then cooled to room temperature. The resulting solids were isolated by filtration to afford, after drying, 1.95 g of crude product. Chiral HPLC analysis indicated 95.2% of the desired 2S,3R-enantiomer. After recrystallizing from absolute ethanol, the content of 2S,3R-enantiomer was enhanced to >99.5%. The salt contained 2 moles of amine per mole of diacid: Mp 141.5- 142.5°C; [α]D 25 = -20.0° (c=1.0, methanol); Chiral HPLC (Bakerbond Chiralcel OD, 4.6 mm x 250 mm, 10.0/90.0/0.1 isopr panol/n- hexane/trifluoroacetic acid, 2.0 mL/min, ambient temperature, UV detection at 215 nm): Retention Time = 6.1 min (minor peak; 2R,3S- enantiomer), Retention Time = 9.5 min (major peak; 2S,3R- enantiomer); Anal. Calcd for C42H54N4O9S: C ,63.78; H, 6.88; N, 7.08; S, 4.05. Found: C, 63.80; H, 6.93; N, 7.12; S, 3.94; *H NMR (DMSO-d6, 270 MHz) δ 8.22-8.16 (m, 4H), 7.70-7.65 (m, 4H), 7.28-7.01 (m, 9H), 4.53 (d, IH, J=3.4 Hz), 4.33-4.26 (q, 2H, J=6.7 Hz), 4.05 (d, IH, 3.4 Hz), 2.90- 2.84 (m, IH), 2.66-2.34 (m, 7H), 1.53 (m, 4H), 1.37 (d, 6H, J=6.8 Hz), 1.29 (s, 8H).
Example 3 Determination and Confirmation of Absolute Configuration Both (S)-β-[(2-carboxyethyl)thio]-2-(8-phenyloctyl)- benzenepropanoic acid and [R-(R*,S*)]-β-[(2-carboxyethyl)thio]-α- hydroxy-2-(8-phenyloctyl)benzenepropanoic acid react with two molar equivalents of (R)-4-iodo-α-methylbenzenemethanamine to produce highly crystalline salts. In each of these salts, the absolute configuration of the diacid portion was determined unambiguously by single crystal x-ray analysis.
In order to correlate this information to the salts obtained in Examples 1 and 2, each salt was treated with aqueous acid and extracted with ethyl acetate. By analyzing the extracts on an HPLC column (cellulose tris-3,5-dimethylphenylcarbamate chiral stationary phase, coated on silica gel) and comparing retention times to authentic samples of the racemates, it was determined that the diacid portion of the salt from Example 1 possessed the S-configuration, and the diacid portion of the salt from Example 2 possessed the 2S,3R-configuration.

Claims

Claims: 1. A salt of formula I
Figure imgf000011_0001
where:
A is 1 and X is 1 or 2;
Rl is Cδ to C13 alkyl, Cη to C12 alkoxy, C7 to C12 alkylthio, Cio to C 12 1-alkynyl, 10-undecynyloxy, 11-dodecynyl, phenyl-C4 to Ci o alkyl, phenyl-C3 to C9 alkoxy, phenylthio-C3 to C9 alkyl with the phenyl unsubstituted or monosubstituted with bromo, chloro, trifluoromethyl, Ci to C4 alkoxy, methylthio or trifluoromethylthio, furyl-C4 to Cio alkyl, trifluoromethyl-C to C12 alkyl or cyclohexyl-Gψ to Cio alkyl; q is 0, 1 or 2, with the proviso that R is not alkylthio or phenylthioalkyl when q is 1 or 2;
Y is COR3, C(R4)H(CH2)mCOR3, or (CH2)θ-l-C-tetrazoIyI;
R3 is 0", amino, or C\ to Cβ alkoxy,
R4 is hydrogen, methyl, Ci to C4-alkoxy, fluoro or hydroxy; m is 0, 1, or 2;
R is (CH2)nCOR6; n is 0 to 6;
R(5 is 0 amino, or Ci to C6-alkoxy; with the proviso that at least one of Y or R must have an R3 or , Re group respectively which is 0".
2. A salt of claim 1 represented by formula (IA).
Figure imgf000011_0002
(IA) where Ri is phenylalkyl.
3. A salt of claim 2 where R is (C__2)i-3 CORβ.
4. A salt of claim 3 represented by the 3-arylpropionate of formula (IB).
Figure imgf000012_0001
5. A salt of claim 4 where Ri is phenyl-C4 to Cio alkyl or Cs to
C13 alkyl.
6. A salt of claim 5 which is the bis-(R)-4-nitro-α- methylbenzenemethanamine salt of (S)-β-[(2-carboxyethyl)thio]-2-(l - dodecy!)benzenepropanoic acid.
7. A salt of claim 5 which is the bis-(R)-4-nitro-α- methylbenzenemethanamine salt of (S)-β-[(2-carboxyethyl)thio]-2-(8- phenyloctyl)benzenepropanoic acid.
8. A salt of claim 3 represented by formula (IC).
Figure imgf000012_0002
9. A salt of claim 8 where Ri is a phenyl-C4 to Cio alkyl or Cs t
Ci3 alkyl.
10. A salt of claim 9 which is the bis-(R)-4-nitro-α-methyl- benzenemethanamine salt of (R)-α-[(2-carboxyethyl)thio]-2-(l - dodecyI)benzeneacetic acid.
1 1. A salt of claim 9 which is the bis-(R)-4-nitro-α-methyl- benzenemethanamine salt of (R)-cc-[(2-carboxyethyl)thio]-2-(8- phenyloctyl)benzeneacetic acid.
12. A salt of claim 1 represented by formula (ID).
Figure imgf000013_0001
13. A salt of claim 12 where Ri is a phenyl-C4 to Cio-alkyl.
14. A salt of claim 13 which is the bis-(R)-4-nitro-α- methylbenzenemethanamine salt of [R-(R*,S*)]-β-[(2- carboxyethyl)thio]-α-hydroxy-2-(8-phenyloctyl)benzenepropanoic acid.
15. A process for separating a single isomer from a racemic mixture of a compound of formula II
Figure imgf000013_0002
where:
Rl is Cs to Ci3 alkyl, Cη to C12 alkoxy, C7 to C12 alkylthio, Cio to C 12 1-alkynyl, 10-undecynyloxy, 11-dodecynyl, phenyl-C_j. to Ci o alkyl, phenyl-C3 to C9 alkoxy, phenylthio-C3 to C9 alkyl with the phenyl optionally mono substituted with bromo, chloro, trifluoromethyl, Ci to C4 alkoxy, methylthio or trifluoromethylthio, furyl-C4 to Cio alkyl, trifluoromethyl-Cγ to C12 alkyl or cyclohexyl-C4 to Cio alkyl; q is 0, 1 or 2, with the proviso that Ri is not alkylthio or phenylthioalkyl when q is 1 or 2;
Y is COR3' C(R4)H(CH2)mCOR3', or (0_2)0-l-C-tetrazolyl; R3« is OH, amino, or Ci to C_δ alkoxy, R4 is hydrogen, methyl, Ci to C4 -alkoxy, fluoro or hydroxy; m is 0, 1, or 2; R is (CH2)nCOR6'; n is 0 to 6;
Rg' is OH, amino, or Ci to Cό-alkoxy; with the proviso that at least one of R3' or R6' is -OH or a salt thereof, which process comprises: (i). treating a racemic mixture of formula II with between abo_ - 0.5 to 2.5 equivalents, relative to the number of carboxylic acid groups in formula (II), of (R)-4-nitro-α-methylbenzenemethanamine;
(ii). recovering a crystalline salt; and (iii). converting the salt to an acid or a pharmaceutically acceptable salt.
16. The process of claim 15 where the separated isomer is a compound of formula
Figure imgf000014_0001
17. The process of claim 16 where Ri is a phenyl-Gψ to Cio-alky or Cs to C13 alkyl.
18. The process of claim 17 which gives the isomer (S)-β-[(2- carboxyethyl)thio]-2-(l-dodecyl)benzenepropanoic acid, or (S)-β-[(2- carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid.
19. The method of claim 15 where the separated isomer is that of formula
Figure imgf000014_0002
20. The process of claim 19 where Ri is a phenyl-C4 to Cio alkyl or Cs to C13 alkyl.
21. The process of claim 20 which gives the isomer (R)-α-[(2- carboxyethyI)thio]-2-(l-dodecyl)benzeneacetic acid or (R)-α-[(2- carboxyethyl)thio]-2-(8-phenyloctyl)benzeneacetic acid.
22. The process of claim 15 where the separated isomer is represented by the formula
Figure imgf000014_0003
23. The process of claim 22 where Ri is a phenyl-C4 to Cio-alky
24. The process of claim 23 which gives the isomer [R-(R*,S*)]~ [(2-carboxyethyl)thio]-α-hydroxy-2-(8-phenyloctyl)benzenepropanoic acid.
PCT/US1991/006862 1990-09-21 1991-09-20 Crystallization of optical isomers of leukotriene antagonists Ceased WO1992005151A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SK21993A SK21993A3 (en) 1990-09-21 1991-09-20 (r)-4-nitro-alfa-methyl-benzenemethanamine salts
AU87675/91A AU662299B2 (en) 1990-09-21 1991-09-20 Crystallization of optical isomers of leukotriene antagonists
CS93451A CZ45193A3 (en) 1990-09-21 1991-09-20 Salts of (r)-4-nitro-alphamethyl benzene methaneamine
KR1019930700813A KR930702284A (en) 1990-09-21 1993-03-17 Crystallization of optical isomers of leukotriene antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58612490A 1990-09-21 1990-09-21
US586,124 1990-09-21

Publications (1)

Publication Number Publication Date
WO1992005151A1 true WO1992005151A1 (en) 1992-04-02

Family

ID=24344408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006862 Ceased WO1992005151A1 (en) 1990-09-21 1991-09-20 Crystallization of optical isomers of leukotriene antagonists

Country Status (21)

Country Link
US (1) US5288900A (en)
EP (1) EP0552254A1 (en)
JP (1) JPH06501269A (en)
KR (1) KR930702284A (en)
CN (1) CN1060653A (en)
AU (1) AU662299B2 (en)
CA (1) CA2091245A1 (en)
CZ (1) CZ45193A3 (en)
IE (1) IE913308A1 (en)
IL (1) IL99578A0 (en)
MX (1) MX9101206A (en)
MY (1) MY131049A (en)
NZ (1) NZ239875A (en)
PL (1) PL296247A1 (en)
PT (1) PT99021A (en)
SK (1) SK21993A3 (en)
TW (1) TW221805B (en)
WO (1) WO1992005151A1 (en)
YU (1) YU157091A (en)
ZA (1) ZA917560B (en)
ZW (1) ZW13191A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505056A1 (en) * 2003-08-07 2005-02-09 Bayer Chemicals AG Enantiomerically enriched 1-phenylethylamines

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070102717A (en) * 2005-01-24 2007-10-19 신벤션 아게 Metal-containing composite materials

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313697A1 (en) * 1987-10-29 1989-05-03 Smithkline Beecham Corporation Leukotriene antagonists
EP0365149A2 (en) * 1988-09-23 1990-04-25 Smithkline Beecham Corporation Leukotriene antagonist prodrugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874792A (en) * 1985-04-19 1989-10-17 Smithkline Beckman Corporation Thiophenyl Alkanoic acids useful as leukotriene antagonists
US4845272A (en) * 1987-07-10 1989-07-04 Kuraray Co., Ltd. Process for the optical resolution of (±)-cis or (±)-trans-permethric acid
IT1217988B (en) * 1988-01-28 1990-03-30 Ind Chimica Profarmaco Spa PROCEDURE FOR THE OPTICAL RESOLUTION OF A PACEMO
US4904822A (en) * 1988-02-19 1990-02-27 Kuraray Co., Ltd. Process for the optical resolution of (+)-2-hydroxy-4-phenylbutanoic acid
IT1226300B (en) * 1988-07-26 1990-12-27 Zambon Spa PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE SYNTHESIS OF DILTIAZEM.
EP0365189B1 (en) * 1988-10-21 1995-06-14 Kabushiki Kaisha Kosmek Quick-acting coupling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313697A1 (en) * 1987-10-29 1989-05-03 Smithkline Beecham Corporation Leukotriene antagonists
EP0365149A2 (en) * 1988-09-23 1990-04-25 Smithkline Beecham Corporation Leukotriene antagonist prodrugs

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505056A1 (en) * 2003-08-07 2005-02-09 Bayer Chemicals AG Enantiomerically enriched 1-phenylethylamines
CN1310870C (en) * 2003-08-07 2007-04-18 拜尔化学品股份公司 Enantiomerically enriched 1-phenylethylamines

Also Published As

Publication number Publication date
ZW13191A1 (en) 1992-02-05
MX9101206A (en) 1992-05-04
PL296247A1 (en) 1993-09-06
JPH06501269A (en) 1994-02-10
IL99578A0 (en) 1992-08-18
CA2091245A1 (en) 1992-03-22
AU662299B2 (en) 1995-08-31
PT99021A (en) 1992-12-31
CN1060653A (en) 1992-04-29
ZA917560B (en) 1992-09-30
CZ45193A3 (en) 1994-02-16
YU157091A (en) 1994-01-20
US5288900A (en) 1994-02-22
KR930702284A (en) 1993-09-08
IE913308A1 (en) 1992-02-25
TW221805B (en) 1994-03-21
AU8767591A (en) 1992-04-15
NZ239875A (en) 1994-06-27
EP0552254A1 (en) 1993-07-28
MY131049A (en) 2007-07-31
SK21993A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
JP2556720B2 (en) Novel polyamine derivatives
JP2505728B2 (en) (Acyloxyalkoxy) carbonyl derivatives as bioreversible precursor moieties for primary and secondary amine functional groups in drugs
EP0711272A1 (en) Indane and tetrahydronaphthalene derivatives as calcium channel antagonists
AU662299B2 (en) Crystallization of optical isomers of leukotriene antagonists
JP4972542B2 (en) Thio-substituted arylmethanesulfinyl derivatives
FR2617402A1 (en) THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION AND MEDICAMENTS CONTAINING SAME
US6229041B1 (en) Preparation of S-aryl-cysteine and its derivatives
AU2002344438B2 (en) Process for producing (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid and its intermediate
AP371A (en) Amine salts of leukotrine antagonist and its use for crystallizing selectively optical isomers thereof.
JPH09157229A (en) Method for racemization of optically active 1-phenylethylamine derivative
US6765109B1 (en) Preparation of S-aryl-cysteine and its derivatives
US20200377456A1 (en) Process for the preparation of glycopyrrolate tosylate
US7291746B2 (en) Process for obtaining an antiepileptic agent
JP2005132815A (en) Optically active sulfonic acid compound
US20120330030A1 (en) Enantioselective Synthesis of y-amino-a, B-unsuturated carboxylic acid derivatives
WO2025136150A1 (en) Method for producing dexmedetomidine and pharmaceutically acceptable salts thereof
EP1236715A2 (en) Process for S-Aryl cysteine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CS JP KR PL US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2091245

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 21993

Country of ref document: SK

Ref document number: PV1993-451

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1991918951

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991918951

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1993-451

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1991918951

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1993-451

Country of ref document: CZ